Table 2.
Synthetic Peptides, second vaccination and immunomonitoring
| ID | Amino acid sequence | HLA-restriction | Source protein, HLA-restriction | AA position within source protein |
|---|---|---|---|---|
| CMV-VPAP | VTEHDTLLY | HLA-A*01 | Human cytomegalovirus, DNA polymerase processivity factor (hCMV, VPAP) | 245–253 |
| CMV-pp65 | YSEHPTFTSQY | HLA-A*01 | Human cytomegalovirus, 65 kDa phosphoprotein (hCMV, pp65) | 363–373 |
| CMV-VIE1 | ELRRKMMYM | HLA-B*08 | Human cytomegalovirus, 55 kDa immediate-early protein 1 (hCMV, VIE1) | 199–207 |
| EBV-GP350 | PRPVSRFLGNNSILY | HLA-DR | Epstein-Barr virus, Envelope Glycoprotein GP350 (EBV, gp350) | 268–282 |
| CMV-pp65283–299 | KPGKISHIMLDVAFTSH | HLA-DR | Human cytomegalovirus, 65 kDa phosphoprotein (hCMV, pp65) | 283–299 |
| CMV-pp65510–524 | YQEFFWDANDIYRIF | HLA-DR | Human cytomegalovirus, 65 kDa phosphoprotein (hCMV, pp65) | 510–524 |